The Scientists Who Cured Blindness Just Won the Breakthrough Prize. Their Business Is Another Story.

Jean Bennett, Albert Maguire, and Katherine High won the 2026 Breakthrough Prize in Life Sciences on Friday — the scientists who proved gene therapy could work in a human being. Their treatment, Luxturna, became the first FDA-approved gene therapy for a genetic disease when it cleared regulators in December 2017. It replaced a defective gene in the eyes of children born with a rare form of inherited blindness, letting them see. The prize is the field's answer to a question these three spent three decades answering: yes, this could be real.

The harder question is whether it scales.

Luxturna launched at $850,000 per patient, or $425,000 per eye NBC News. Analysts called it a scientific triumph and a financial test case for every gene therapy that would follow. Spark Therapeutics, the company High co-founded to commercialize the therapy, sold $27 million worth of it in the year before Roche acquired the company for $4.8 billion in 2019 C&EN. That valuation, investors were told, reflected Luxturna's potential and the platform behind it.

In 2024, Luxturna generated roughly $20 million in sales, down 59 percent year over year FiercePharma. Roche, which now owns the therapy, took a $2.4 billion impairment on the Spark acquisition in April, writing down the value it had once assigned to the gene therapy platform. Nearly all eligible patients with the RPE65 mutation in the United States have already been treated Breakthrough Prize Foundation. The addressable population, it turns out, was small and largely reached.

The science works. The business model is still being figured out.

Bennett and Maguire, the husband-and-wife team who invented and developed the therapy at the University of Pennsylvania, waived any financial stake in the commercial product before the human trial began Penn Medicine. High, then at Children's Hospital of Philadelphia, joined them in 2005 to run the pivotal study that would prove the concept in people Breakthrough Prize Foundation. The FDA approved Luxturna on that evidence Spark Therapeutics. The Breakthrough Prize cited the work as foundational for the field.

It has been. Since Luxturna, hundreds of gene therapy trials have launched, including more than 100 targeting retinal diseases. More than half a dozen are in late-stage testing. The regulatory pathways, manufacturing approaches, and safety data that Bennett, Maguire, and High worked out opened doors that are still being walked through. The prize is not wrong about the science.

What it does not answer is the economics. If the first FDA-approved gene therapy cannot generate meaningful commercial returns even with a $4.8 billion acquisition price and a $3 million Breakthrough Prize attached to its creators, the companies working on the next wave of gene therapies have some hard conversations ahead. The scientists solved the biology. The field is still solving the business.